Nos

0

essais cliniques ouverts

Vous êtes patient : votre médecin est à votre disposition pour vous expliquer si votre pathologie vous rend eligible à un essai.

Qu’est ce qu’un essai clinique ?

Plus d’informations via l’INCa

Vous êtes médecin : Vous avez un patient éligible à l’un de ces essais ? Nous vous invitons à joindre le contact indiqué pour chaque essai.

Date de mise à jour : Septembre 2021

PAR
LOCALISATION
TUMORALE

NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03968419 This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) 2 Cancer du poumon non à petites cellules (NSCLC) Critères Stade IB-IIIA 1 marie.wislez@aphp.fr Cochin
NCT03447769 Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer (Canopy-A) 3 Cancer du poumon non à petites cellules (NSCLC) Critères IIA-IIIA and IIIB (atteintes résiduelles N2 seulement) 2 marie.wislez@aphp.fr Cochin
NCT03924869 Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) 3 Cancer du poumon non à petites cellules (NSCLC) Critères I or IIA 1 marie.wislez@aphp.fr Cochin
NCT04026412 A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) 3 Cancer du poumon non à petites cellules (NSCLC) Critères Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) 1 marie.wislez@aphp.fr Cochin
NCT03977194 Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY) 3 Cancer du poumon non à petites cellules (NSCLC) Critères metastatic 1 marie.wislez@aphp.fr Cochin
NCT04547504 PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE) 3 Cancer du poumon non à petites cellules (NSCLC) PDL1 (expression >50%) Critères Stage IV or . Unresectable and non-eligible to radiotherapy stage III 1 marie.wislez@aphp.fr Cochin
NCT04475939 Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) 3 Cancer du poumon non à petites cellules (NSCLC) Without known alteration Critères Advanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) 2 marie.wislez@aphp.fr Cochin
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) 3 Cancer du poumon non à petites cellules (NSCLC) Ret-fusion Critères Advanced or metastatic : Stage IIIB-IIIC or Stage IV 1 marie.wislez@aphp.fr / elizabeth.fabre@aphp.fr Cochin/HEGP
NCT04323436 Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations 2 Cancer du poumon non à petites cellules (NSCLC) METΔex14 mutation Critères  locally advanced or metastatic 1 marie.wislez@aphp.fr Cochin
NCT04233021 Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) 2 Cancer du poumon non à petites cellules (NSCLC) EGFR Critères metastatic (Leptomeningeal & Brain) 2, 3 or 4 marie.wislez@aphp.fr Cochin
NCT03940703 A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) 2 Cancer du poumon non à petites cellules (NSCLC) MET Amplified, EGFR Critères Locally advanced or metastatic 2 marie.wislez@aphp.fr Cochin
NCT04111705 Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) 2 Cancer du poumon non à petites cellules (NSCLC) ALK rearrangement Critères locally advanced or metastatic (Stage IIIB or IV ) 2 marie.wislez@aphp.fr Cochin
NCT03351361 Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY) 3 Cancer du poumon non à petites cellules (NSCLC) Critères Stage IV or non-treatable by radiotherapy or surgery stage III 1 marie.wislez@aphp.fr Cochin
NCT04624204 Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) 3 Cancer du poumon à petites cellules (SCLC) Critères locally (Limited-Stage SCLC (Stage I-III) 1 marie.wislez@aphp.fr Cochin
NCT03976375 Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) 3 Cancer du poumon non à petites cellules (NSCLC) Critères metastatic (Stage IV: M1a, M1b, M1c) 2 jacques.medioni@aphp.fr HEGP
NCT04154956 SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) 3 Cancer du poumon non à petites cellules (NSCLC) CEACAM5 positive Critères metastatic 2 jacques.medioni@aphp.fr HEGP
NCT04526782 ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) 2 Cancer du poumon non à petites cellules (NSCLC) BRAF Critères Stage IV 2 marie.wislez@aphp.fr Cochin
NCT03833154 Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4) 3 Carcinoma, Non-Small-Cell Lung Critères Stage I to II NSCLC elizabeth.fabre@aphp.fr HEGP
NCT03178552 A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST 2,3 Non-Small Cell Lung Cancer Critères Unresectable stage IIIB or IV >1 felizabeth.fabre@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04006262 Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma 2 Adénocaecinome oeso-gastrique dMMR et/ou MSI Critères Péri-op Péri-op Julien Taieb : jtaieb75@gmail.com HEGP
NCT03006432 Phase III randomised trial to evaluate FOLFOX with or without docetaxel (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric carcinoma 3 Adénocaecinome oeso-gastrique HER-2 négative Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT03959293 Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma 2 Adénocaecinome oeso-gastrique Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03760822 Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients 2 Adénocaecinome oeso-gastrique Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT03722108 Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas 2 Adénocaecinome oeso-gastrique Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy 3 Carcinome Epidermoïde de l’oesophage Critères LA 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03748134 Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma 3 Carcinome Epidermoïde de l’oesophage Critères LA-Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03719924 Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma 3 Carcinome Epidermoïde de l’oesophage Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03783442 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma 3 Esophageal Squamous Cell Carcinoma (ESCC) Critères Unresectable, locally advanced recurrent or metastatic 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02502370 Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma 3 INTESTIN GRELE Critères Adjuvant Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04163887 Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases (METALAP) Non Applicable / Chirurgie Métastase hépatique de cancer du colon Critères Metastatique david.fuks@aphp.fr Cochin
NCT04120701 Circulating tumor dna based decision for adjuvant treatment in colon cancer stage II 3 Cancer du colon Critères Stage II-III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT02945033 Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (ASPIK French) 3 Cancer du colon PI3K Critères Stage II-III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT02967289 A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high- risk stage III colon cancer in adjuvant setting 3 Cancer du colon Critères Stage III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT02355379 Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more 3 Cancer du colon Critères Stage III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT02885753 Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR) 3 Cancer du colon Critères Métastases hépatiques 1 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT03164655 A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy: SULTAN (improving SUrgery of Liver metastases: a Trial of the Arterial chemotherapy Network) 2 Cancer du colon Critères Métastases hépatiques 2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT04456699 A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) 3 Cancer du colon Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03584711 A Phase II Study Evaluating FOLFOX + Panitumumab According to a « Stop and go » Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation 2 Cancer du colon RAS wt; BRAF wt Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT04034459 FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC 2 Cancer du colon BRAF muté (V600E).   RAS wt Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03186326 Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) 2 Cancer du colon MSI Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT04392479 TWICE-IRI: Optimization of second-line therapy with aflibercept, irinotecan (day 1 or day 1,3), 5-Fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study. 3 Cancer du colon Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT03829462 A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1 3 Cancer du colon  génotype A/A (rs9344) de la cycline D1 Critères Métastatique ≥2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT04737187 Phase III study of trifluridine/tipiracil in combination with bevacizumab vs trifluridine/tipiracil single agent in patients with refractory metastatic colorectal cancer 3 Cancer du colon Critères Métastatique 2,3 Julien Taieb : jtaieb75@gmail.com HEGP
NCT04450836 Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) 2 Cancer du colon Critères Métastatique ≥2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03875781 Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemotherapy followed by chemoradiotherapy for locally advanced resectable rectal cancer 2 Cancer du Rectum Critères Pré-opératoire Pré-op Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04791735 Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma (LapCHC) Non Applicable / Chirurgie Hepatocellular carcinoma Critères Solitary or multifocal resectable david.fuks@aphp.fr Cochin
NCT03656536 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma 3 Cholangiocarcinome Réarrangement FGFR2 Critères LA-Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03364530 Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma 2 Intra-hepatic Cholangiocarcinoma (GEMOXIA-02) Critères Non résecable-Non Métastatique 2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT02924376 Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) 2 Cholangiocarcinoma FGFR2 Critères >ou= 2 romain.coriat@aphp.fr Cochin
NCT04163900 Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer 3 Biliary Tract Cancer Critères locally advanced, unresectable or metastatic 1 ou 2 romain.coriat@aphp.fr Cochin
NCT03773302 Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations 3 Cholangiocarcinoma FGFR2 fusions/translocations Critères unresectable locally advanced or metastatic 1 romain.coriat@aphp.fr Cochin
NCT03630640 Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP) 2 Hepatocellular Carcinoma Critères 2 stanislas.pol@aphp.fr Cochin
NCT04163887 Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases (METALAP) Non Applicable / Chirurgie Métastase hépatique de cancer du colon Critères Metastatique david.fuks@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03679169 Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (REMIND-01) Non Applicable / Chirurgie Cancer du pancréas Critères Invasive resectable david.fuks@aphp.fr Cochin
NCT03693677 First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI 2 Adénocaecinome du Pancreas Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT04348045 Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02) 2 Adénocaecinome du Pancreas BRCA / KRAS Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT04167007 FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX 3 Adénocaecinome du Pancreas Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3) 3 Adenocarcinoma of the Pancreas Critères metastatic 1 romain.coriat@aphp.fr Cochin
NCT02959879 Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (PANACHE01) 2 Pancreatic Duct Adenocarcinoma Critères Resectable adenocarcinoma neoadjuvant romain.coriat@aphp.fr Cochin
NCT02676349 Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) 2 Pancreatic Carcinoma Critères Borderline resectable status neoadjuvant romain.coriat@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03351296 Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors 2 tumeur neuroendocrine du pancréas Critères LA-Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT02820857 Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer 2 tumeur neuroendocrine Critères LA-Métastatique 2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03591731 A GCO trial exploring the efficacy and safety of Nivolumab monotherapy or Nivolumab plus Ipilimumab in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) 2 tumeur neuroendocrine Critères LA-Métastatique 2,3 Julien Taieb : jtaieb75@gmail.com / romain.coriat@aphp.fr / Elizabeth.fabre@aphp.fr HEGP/Cochin
NCT04268121 Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas (NEONEC) 2 Neuroendocrine Carcinoma in gastro Critères localized neoadjuvant romain.coriat@aphp.fr Cochin
NCT04325425 Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (FOLFIRINEC) 2 Neuroendocrine Carcinoma in gastro Critères Grade 3 or high grade MiNEN 1 romain.coriat@aphp.fr Cochin
NCT02260505 A randomized, multicentre, Phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumours (GIST) 3 GIST KIT positivity Critères Adjuvant Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03598270 Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) 3 Ovarian Carcinoma Critères high- grade serous or endometrioid ovarian, primary peritoneal or tubal carcinoma 1,2,3 bruno.borghese@aphp.fr / anne-sophie.bats@aphp.fr Cochin/HEGP
NCT03249142 Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV) 1,2 ovarian cancer,fallopian tube Critères newly diagnosed 1 jerome.alexandre@aphp.fr Cochin
NCT03752216 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NiQoLe) 4 Ovarian Cancer Critères high grade epithelial ovarian cancer 2 jerome.alexandre@aphp.fr Cochin
NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) 3 Epithelial Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer Critères high-grade 2 bruno.borghese@aphp.fr Cochin
NCT02866370 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC) 2 Ovarian Clear Cell Carcinoma Endometrial Clear Cell Carcinoma Critères Progressive or recurrent >ou= 2 bruno.borghese@aphp.fr Cochin
NCT03842982 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) 3 Ovarian Cancer Critères Stage III 2 anne-sophie.bats@aphp.fr HEGP
NCT03737643 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. 3 Advanced Ovarian Cancer Critères advanced (Stage III-IV) 1 anne-sophie.bats@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04246489 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer 2 Uterine Cervical Neoplasms Critères advanced unresectable and/or metastatic 1,2 bruno.borghese@aphp.fr Cochin
NCT03556839 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) 3 Carcinoma of the Cervix Critères metastatic (stage IVB), persistent, or recurrent 1 anne-sophie.bats@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03517449 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) 3 Endometrial Neoplasms Critères advanced, recurrent or metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent 3 Endometrial Neoplasms Critères newly diagnosed 1 jerome.alexandre@aphp.fr Cochin
NCT02866370 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC) 2 Ovarian Clear Cell Carcinoma Endometrial Clear Cell Carcinoma Critères Progressive or recurrent >ou= 2 bruno.borghese@aphp.fr Cochin
NCT04463771 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. 2 Endometrial Cancer Critères Advanced or Metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT03745950 UTOLA: UTerin OLAparib (UTOLA 2 Endometrial Cancer MSI-High, MMR, POLE, FGFR mutations/alterations Critères advanced/metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03968419 This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) 2 Cancer du poumon non à petites cellules (NSCLC) Critères Stade IB-IIIA 1 marie.wislez@aphp.fr Cochin
NCT03447769 Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer (Canopy-A) 3 Cancer du poumon non à petites cellules (NSCLC) Critères IIA-IIIA and IIIB (atteintes résiduelles N2 seulement) 2 marie.wislez@aphp.fr Cochin
NCT03924869 Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) 3 Cancer du poumon non à petites cellules (NSCLC) Critères I or IIA 1 marie.wislez@aphp.fr Cochin
NCT04026412 A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) 3 Cancer du poumon non à petites cellules (NSCLC) Critères Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) 1 marie.wislez@aphp.fr Cochin
NCT03977194 Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY) 3 Cancer du poumon non à petites cellules (NSCLC) Critères metastatic 1 marie.wislez@aphp.fr Cochin
NCT04547504 PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE) 3 Cancer du poumon non à petites cellules (NSCLC) PDL1 (expression >50%) Critères Stage IV or . Unresectable and non-eligible to radiotherapy stage III 1 marie.wislez@aphp.fr Cochin
NCT04475939 Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) 3 Cancer du poumon non à petites cellules (NSCLC) Without known alteration Critères Advanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) 2 marie.wislez@aphp.fr Cochin
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) 3 Cancer du poumon non à petites cellules (NSCLC) Ret-fusion Critères Advanced or metastatic : Stage IIIB-IIIC or Stage IV 1 marie.wislez@aphp.fr / francoise.lepimpec-barthes@aphp.fr Cochin/HEGP
NCT04323436 Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations 2 Cancer du poumon non à petites cellules (NSCLC) METΔex14 mutation Critères  locally advanced or metastatic 1 marie.wislez@aphp.fr Cochin
NCT04233021 Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) 2 Cancer du poumon non à petites cellules (NSCLC) EGFR Critères metastatic (Leptomeningeal & Brain) 2, 3 or 4 marie.wislez@aphp.fr Cochin
NCT03940703 A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) 2 Cancer du poumon non à petites cellules (NSCLC) MET Amplified, EGFR Critères Locally advanced or metastatic 2 marie.wislez@aphp.fr Cochin
NCT04111705 Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) 2 Cancer du poumon non à petites cellules (NSCLC) ALK rearrangement Critères locally advanced or metastatic (Stage IIIB or IV ) 2 marie.wislez@aphp.fr Cochin
NCT03351361 Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY) 3 Cancer du poumon non à petites cellules (NSCLC) Critères Stage IV or non-treatable by radiotherapy or surgery stage III 1 marie.wislez@aphp.fr Cochin
NCT04624204 Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) 3 Cancer du poumon à petites cellules (SCLC) Critères locally (Limited-Stage SCLC (Stage I-III) 1 marie.wislez@aphp.fr Cochin
NCT03976375 Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) 3 Cancer du poumon non à petites cellules (NSCLC) Critères metastatic (Stage IV: M1a, M1b, M1c) 2 jacques.medioni@aphp.fr HEGP
NCT04154956 SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) 3 Cancer du poumon non à petites cellules (NSCLC) CEACAM5 positive Critères metastatic 2 jacques.medioni@aphp.fr HEGP
NCT04526782 ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) 2 Cancer du poumon non à petites cellules (NSCLC) BRAF Critères Stage IV 2 marie.wislez@aphp.fr Cochin
NCT03833154 Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4) 3 Carcinoma, Non-Small-Cell Lung Critères Stage I to II NSCLC francoise.lepimpec-barthes@aphp.fr HEGP
NCT03178552 A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST 2,3 Non-Small Cell Lung Cancer Critères Unresectable stage IIIB or IV >1 francoise.lepimpec-barthes@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03549715 NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO) 1,2 Infiltrating Bladder Urothelial Carcinoma Critères invasive Adjuvant jacques.medioni@aphp.fr / michael.peyromaure@aphp.fr HEGP/Cochin
NCT04209114 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer 3 Bladder cancer Critères muscle-invasive pré/post-op jacques.medioni@aphp.fr HEGP
NCT03799835 Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN) 3 Bladder Cancer Critères T1 tumor and/or High grade (WHO 2004) and/or Grade 3 (WHO1973) and/or Carcinoma in situ 1,2 michael.peyromaure@aphp.fr / stephane.oudard@aphp.fr Cochin/HEGP
NCT04149574 A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) 3 Bladder Cancer Critères Persistent or recurrent disease >ou= 2 michael.peyromaure@aphp.fr Cochin
NCT03924895 Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer 3 Bladder cancer Critères Péri-op michael.peyromaure@aphp.fr / stephane.oudard@aphp.fr Cochin/HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02760498 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma 2 Carcinome épidermoïde cutané avancé Critères locally advanced or metastatic 1,2 selim.aractingi@aphp.fr Cochin
NCT03469804 Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma (KAPKEY) 2 Kaposi Sarcoma Critères Progressive disease >ou= 2 selim.aractingi@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03809988 PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA) 2 breast cancer ER + or/and PgR + & HER2 – Critères Advanced 1,2 jacques.medioni@aphp.fr HEGP
NCT03659136 The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread 2 breast cancer ER + or/and PgR + & HER2 – Critères Locally advanced or metastatic 1,2 jacques.medioni@aphp.fr HEGP
NCT03701334 A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) 3 Breast cancer ER + or/and PgR + & HER2 – Critères early invasive 1 jacques.medioni@aphp.fr HEGP
NCT04478266 Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer 2,3 Breast Cancer ER + and HER2 – Critères loco-regional recurrent or metastatic 1 anne-sophie.bats@aphp.fr HEGP
NCT04109066 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) 3 Breast cancer ER + and HER2 – Critères Localized invasive 1 anne-sophie.bats@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03809988 PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA) 2 breast cancer ER + or/and PgR + & HER2 – Critères Advanced 1,2 jacques.medioni@aphp.fr HEGP
NCT03659136 The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread 2 breast cancer ER + or/and PgR + & HER2 – Critères Locally advanced or metastatic 1,2 jacques.medioni@aphp.fr HEGP
NCT03701334 A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) 3 Breast cancer ER + or/and PgR + & HER2 – Critères early invasive 1 jacques.medioni@aphp.fr HEGP
NCT04478266 Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer 2,3 Breast Cancer ER + and HER2 – Critères loco-regional recurrent or metastatic 1 anne-sophie.bats@aphp.fr HEGP
NCT04109066 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) 3 Breast cancer ER + and HER2 – Critères Localized invasive 1 anne-sophie.bats@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02313389 Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma (BLOCAGE-01) 3 Primary Central Nervous System Lymphoma Critères newly diagnosed 1 didier.bouscary@aphp.fr Cochin
NCT02416388 Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1) 2,3 Acute Myeloid Leukemia (AML) Critères newly diagnosed de novo or secondary type AML 1 didier.bouscary@aphp.fr Cochin
NCT02619630 Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) (GRAALL-2014/T) 2 T-cell Adult Acute Lymphoblastic Leukemia Critères 1 didier.bouscary@aphp.fr Cochin
NCT03993912 Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03) 3 Multiple Myeloma Critères 1 didier.bouscary@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02760498 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma 2 Carcinome épidermoïde cutané avancé Critères locally advanced or metastatic 1,2 selim.aractingi@aphp.fr Cochin
NCT03469804 Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma (KAPKEY) 2 Kaposi Sarcoma Critères Progressive disease >ou= 2 selim.aractingi@aphp.fr Cochin
Contenu d’accordéon
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion 1,2 : First in human Solid Tumours / NSCLC / Pancreatic Cancer NRG1 Fusion NRG1 fusion Critères   2 marie.wislez@aphp.fr Cochin
NCT03157128 Phase 1/2 Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) 1,2 : First in human pan-tumoral Ret-fusion Critères locally advanced or metastatic 1,2 jacques.medioni@aphp.fr HEGP
NCT02715284 Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET) 1 pan-tumoral Critères  recurrent or advanced solid tumor 2 jacques.medioni@aphp.fr HEGP
NCT03679767 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) 2 pan-tumoral (lung & urothelial cancer) PDL1 expression Critères locally advanced or metastatic tumors 1 jacques.medioni@aphp.fr HEGP
NCT03899155 Pan Tumor Nivolumab Rollover Study 2 pan-tumoral Critères jacques.medioni@aphp.fr HEGP
NCT03692065 API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT) 3 Cancer-associated Thrombosis – in gastro cancer Critères tout stade toute ligne romain.coriat@aphp.fr Cochin
NCT04282590 A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study) 2 Chemotherapy-induced Peripheral Neuropathy – in Gastro cancer Critères 2 romain.coriat@aphp.fr Cochin
NCT03822117 Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207 2 pan-tumoral FGFR genes mutations/translocation Critères advanced or metastatic or is surgically unresectable 2 francois.goldwasser@aphp.fr Cochin
NCT02734004 A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) 1,2 pan-tumoral (Sein, poumon, ovaire, cancer, gastro) Critères Advanced 2 francois.goldwasser@aphp.fr Cochin
NCT03486873 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study 3 pan-tumoral Critères Advanced or Metastatic 2 francois.goldwasser@aphp.fr Cochin
NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer 3 Chemotherapy-induced Thrombocytopenia Critères All Julien Taieb : jtaieb75@gmail.com HEGP
NCT03170960 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors 1,2 pan-tumoral Critères inoperable, locally advanced, metastatic, or recurrent 1 ou 2 jacques.medioni@aphp.fr HEGP
NCT03815643 Avelumab Program Rollover Study 3 pan-tumoral Critères jacques.medioni@aphp.fr HEGP

PAR
ALTERATION GENETIQUE /
MARQUEUR

NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04111705 Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) 2 Cancer du poumon non à petites cellules (NSCLC) ALK rearrangement Critères locally advanced or metastatic (Stage IIIB or IV ) 2 marie.wislez@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04034459 FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC 2 Cancer du colon BRAF muté (V600E). RAS wt Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT04526782 ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) 2 Cancer du poumon non à petites cellules (NSCLC) BRAF Critères Stage IV 2 marie.wislez@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04348045 Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02) 2 Adénocaecinome du Pancreas BRCA / KRASS Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade ligne de traitement Contact Site d’inclusion
NCT04154956 SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) 3 Cancer du poumon non à petites cellules (NSCLC) CEACAM5 positive Critères metastatic 2 jacques.medioni@aphp.fr HEGP
NCTTitre de l’essaiPhaseIndicationAltération génétique / marqueurCritères d’inclusionStadeLigne de traitementContactSite d’inclusion
NCT03829462A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D13Cancer du colongénotype A/A (rs9344) de la cycline D1CritèresMétastatique≥2Julien Taieb : jtaieb75@gmail.comHEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04233021 Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) 2 Cancer du poumon non à petites cellules (NSCLC) EGFR Critères metastatic (Leptomeningeal & Brain) 2, 3 or 4 marie.wislez@aphp.fr Cochin
NCT03940703 A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) 2 Cancer du poumon non à petites cellules (NSCLC) MET Amplified, EGFR Critères Locally advanced or metastatic 2 marie.wislez@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03809988 PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA) 2 breast cancer ER + or/and PgR + & HER2 – Critères Advanced 1,2 jacques.medioni@aphp.fr HEGP
NCT03659136 The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread 2 breast cancer ER + or/and PgR + & HER2 – Critères Locally advanced or metastatic 1,2 jacques.medioni@aphp.fr HEGP
NCT03701334 A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) 3 Breast cancer ER + or/and PgR + & HER2 – Critères early invasive 1 jacques.medioni@aphp.fr HEGP
NCT04478266 Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer 2,3 Breast Cancer ER + and HER2 – Critères loco-regional recurrent or metastatic 1 anne-sophie.bats@aphp.fr HEGP
NCT04109066 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) 3 Breast cancer ER + and HER2 – Critères Localized invasive 1 anne-sophie.bats@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03656536 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma 3 Cholangiocarcinome Réarrangement FGFR2 Critères LA-Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03390504 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations 3 Urothelial Carcinoma FGFR Critères advanced or metastatic 2,3 jacques.medioni@aphp.fr HEGP
NCT04197986 Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations 3 Urothelial Carcinoma FGFR3 Critères invasive adjuvant jacques.medioni@aphp.fr HEGP
NCT02924376 Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) 2 Cholangiocarcinoma FGFR2 Critères >ou= 2 romain.coriat@aphp.fr Cochin
NCT03773302 Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations 3 Cholangiocarcinoma FGFR2 fusions/translocations Critères unresectable locally advanced or metastatic 1 romain.coriat@aphp.fr Cochin
NCT03822117 Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207 2 pan-tumoral FGFR genes mutations/translocation Critères advanced or metastatic or is surgically unresectable 2 francois.goldwasser@aphp.fr Cochin
NCT03745950 UTOLA: UTerin OLAparib (UTOLA 2 Endometrial Cancer MSI-High, MMR, POLE, FGFR mutations/alterations Critères advanced/metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03748641 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) 3 Castration-Resistant Prostatic Cancer HRR gene alteration Critères metastatic 1 ou 2 stephane.oudard@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02260505 A randomized, multicentre, Phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumours (GIST) 3 GIST KIT positivity Critères Adjuvant Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04348045 Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02) 2 Adénocaecinome du Pancreas BRCA / KRAS Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04323436 Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations 2 Cancer du poumon non à petites cellules (NSCLC) METΔex14 mutation Critères locally advanced or metastatic 1 marie.wislez@aphp.fr Cochin
NCT03940703 A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) 2 Cancer du poumon non à petites cellules (NSCLC) MET Amplified, EGFR Critères Locally advanced or metastatic 2 marie.wislez@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03186326 Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) 2 Cancer du colon MSI Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT04006262 Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma 2 Adénocaecinome oeso-gastrique dMMR et/ou MSI Critères Péri-op Péri-op Julien Taieb : jtaieb75@gmail.com HEGP
NCT03745950 UTOLA: UTerin OLAparib (UTOLA 2 Endometrial Cancer MSI-High, MMR, POLE, FGFR mutations/alterations Critères advanced/metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04006262 Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma 2 Adénocaecinome oeso-gastrique dMMR et/ou MSI Critères Péri-op Péri-op Julien Taieb : jtaieb75@gmail.com HEGP
NCT03745950 UTOLA: UTerin OLAparib (UTOLA 2 Endometrial Cancer MSI-High, MMR, POLE, FGFR mutations/alterations Critères advanced/metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion 1,2 : First in human Solid Tumours / NSCLC / Pancreatic Cancer NRG1 Fusion NRG1 fusion Critères 2 marie.wislez@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04547504 PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE) 3 Cancer du poumon non à petites cellules (NSCLC) PDL1 (expression >50%) Critères Stage IV or . Unresectable and non-eligible to radiotherapy stage III 1 marie.wislez@aphp.fr Cochin
NCT03679767 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) 2 pan-tumoral (lung & urothelial cancer) PDL1 expression Critères locally advanced or metastatic tumors 1 jacques.medioni@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02945033 Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (ASPIK French) 3 Cancer du colon PI3K Critères Adjuvant/Stage II-III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) 3 Cancer du poumon non à petites cellules (NSCLC) Ret-fusion Critères Advanced or metastatic : Stage IIIB-IIIC or Stage IV 1 marie.wislez@aphp.fr / francoise.lepimpec-barthes@aphp.fr Cochin/HEGP
NCT03157128 Phase 1/2 Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) 1,2 : First in human pan-tumoral Ret-fusion Critères locally advanced or metastatic 1,2 jacques.medioni@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique / marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03401788 A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) 2 Renal clear cell carcinoma germline VHL alteration Critères localized 1 jacques.medioni@aphp.fr HEGP

TOUS
LES
ESSAIS